Ascendis Pharma A/S

NASDAQ:ASND

Biotechnology

Healthcare
$270.33 -0.02%

-$0.05 today

Market cap
$17.73B
Beta
0.39
P/E (TTM)
24.5
EPS (TTM)
$8.21
52W Low $160.86High $250.74

Volume 0.57M

Average 0.64M

ASND Retained Earnings

Cumulative profits kept in the business rather than paid out as dividends.

Ascendis Pharma A/SNASDAQ: ASND

Retained Earnings · Q3 FY2026 · quarter ended Sep 2026

Retained earnings remains negative

Q3 FY2026 retained earnings was -€1.84B, compared with -€2.71B a year earlier.

Context

  • Retained earnings amounted to 75.8% of total assets at the end of Q3 FY2026, down 158.5 pp from a year earlier.
  • Retained earnings grew in size in 3 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether retained earnings keeps rising in the next quarterly balance sheet after a +32.0% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterSep 2026
-€1.84B+2.0% QoQ
Last fiscal yearDec 2025
-€2.7B-5.5% YoY
Year agoSep 2025
-€2.71B+32.0% since
Retained Earnings past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+32.0%——
1 year-5.5%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Retained Earnings history

EUR · from the balance sheet

Latest · FY2025
(2.7B) EUR
Year-over-year change
-5.5%

Retained Earnings vs competitors

How ASND compares with its peers on the latest reported figures

  • Peers report in different currencies, so retained earnings is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of +32.0% is the 3rd highest of 11, against a peer median of -6.5%.
  • Retained earnings amounts to 75.8% of total assets for ASND, versus a peer median of 98.6%.
ASND Competitors
Retained Earnings for ASND and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
BMRNBioMarin Pharmaceutical Inc.Sep 2026$181.66B USD+90379.6%—1.6%
UTHRUnited Therapeutics CorporationJun 2026$9.16B USD+16.7%+19.3%126.9%
NBIXNeurocrine Biosciences, Inc.Sep 2026$838.4M USD+185.2%—14.9%
CORTCorcept Therapeutics IncorporatedJun 2026$654.61M USD+9.2%+29.5%73.7%
SEPNSepterna, Inc.Sep 2026-$215.51M USD-37.7%—34.8%
MBXMBX Biosciences, Inc. Common StockSep 2026-$347.51M USD-71.7%—69.4%
STOKStoke Therapeutics, Inc.Mar 2026-$547.72M USD-44.9%—123.6%
XERSXeris Biopharma Holdings, Inc.Mar 2026-$669.07M USD+1.8%—170.7%
ASNDAscendis Pharma A/SSep 2026-€1.84B EUR+32.0%—75.8%
RAREUltragenyx Pharmaceutical Inc.Mar 2026-$4.72B USD-14.8%—364.0%
INSMInsmed IncorporatedJun 2026-$5.81B USD-17.7%—276.5%
Peer median (excluding ASND) —-6.5%+24.4%98.6%

Competitors are the stored peer set for ASND. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents446.27M444.77M392.16M559.54M615.78M
Short-term Investments235.8M290.69M7.28M00
Net Receivables2.2M11.91M35.87M166.28M157.63M
Inventory75.41M130.67M208.93M295.61M301.4M
Other Current Assets20.99M13.72M19.9M11.16M0
Total Current Assets805.89M923.47M702.72M1.06B1.11B
Property, Plant & Equipment (Net)126.05M129.1M110.63M98.71M146.42M
Goodwill3.5M3.5M3.5M3.5M3.49M
Intangible Assets1.78M1.33M924K533K214.91K
Long-term Investments145.91M30.42M5.69M13.58M43.38M
Tax Assets00000
Other Non-current Assets1.81M1.92M2.13M2.32M0
Total Non-current Assets279.04M166.27M122.87M118.63M193.5M
Total Assets1.08B1.09B825.59M1.18B1.3B
Account Payables59.42M101.03M94.57M96.39M90.62M
Short-term Debt7M412.98M421.27M491.54M486.32M
Tax Payables198K5.49M2.3M1.22M0
Deferred Revenue2.6M01.18M936K4.94M
Other Current Liabilities24.15M183.49M203.02M317.78M480.63M
Total Current Liabilities100.36M716.78M736.51M907.86M1.07B
Long-term Debt97.97M95.4M223M365.08M385.09M
Deferred Tax Liabilities005.83M7.26M9.62M
Deferred Revenue (Non-current)2.96M14.21M5.95M5M1.12M
Other Non-current Liabilities(97.97M)(95.4M)(84.62M)00
Total Non-current Liabilities100.93M109.61M234.78M377.34M395.83M
Total Liabilities201.29M826.39M971.28M1.29B1.46B
Common Stock7.65M7.68M7.75M8.15M8.32M
Retained Earnings(1.24B)(1.86B)(2.28B)(2.56B)(2.7B)
Accumulated OCI3.78M3.45M721K1.78M(1.75M)
Other Stockholders Equity00000
Minority Interest00000
Total Equity883.64M263.35M(145.7M)(105.71M)(162.75M)
Total Debt209.92M617.57M743.06M856.62M871.41M
Net Debt(236.35M)172.8M350.89M297.07M255.64M

Ascendis Pharma A/S

NASDAQ:ASND

Intrinsic Alpha fair value

Locked

Current Price

$270.33

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.